Leyden Laboratories has announced that it acquired intranasal RNA therapy developer RIGImmune sometime earlier this year. The company also reported results from a Phase 1 study of RIGImmune’s RIG-101, an intranasal innate immune modulator for the treatment of respiratory viruses. Leyden Labs recently announced a a €40 million financing to support development of antiviral nasal sprays, which include the company’s PanFlu (CR9114) antibody nasal spray.
RIGImmune’s candidates are based on the company’s nano-emulsion effective delivery (NEED) formulation platform which RIGImmune acquired when it acquired Subintro, Inc in 2022. Leyden Labs says that RIG-101 “adds a complementary intranasal approach” to the company’s existing pipeline and that the Phase 1 results support advancement into Phase 2 development, with a planned rhinovirus challenge study in asthma patients.
According to Leyden Labs, the Phase 1 study demonstrated expected immune responses in the airway, including expression of interferon-stimulating genes. The trial also demonstrated safety and tolerability of daily dosing at all dose levels for up to 7 days in both healthy volunteers and in asthma patients.
Leyden Labs CEO Koenraad Wiedhaup commented, “At Leyden Labs, our mission is to protect people from the consequences of respiratory viral infections by intervening directly in the airway. The positive Phase 1 results for RIG-101 demonstrate the potential of innate immune modulation as a powerful complement to our broadly protective antibody programs. Together, these approaches broaden our ability to protect vulnerable patients from the consequences of respiratory viral infections.”
Read the Leyden Labs press release
